Why the study?
Current anticoagulants are not completely effective and bleeding concerns limit uptake, making safer factor XI inhibitors an important therapeutic prospect.
Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
May enable safer anticoagulation with lower bleeding; leaves open efficacy confirmation in phase 3 trials.
Caterina et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: